gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin mdco acquisit confirm piii hattr
highlight week novemb novemb medicin compani enter definit
agreement acquir novarti unrat bn announc repres
premium mdco unaffect share price premium unaffect one-week averag price
consist thesi compani expect mdco lead product candid rnai therapeut inclisiran
potenti revolution treatment cardiovascular diseas novemb mdco close
close prior made mdco chardan top pick
januari research chardan mdco thesi play remov mdco chardan
top pick portfolio lock absolut return downgrad mdco buy neutral
unrat major own affili unrat initi phase
trial neuro-ttransform antisens therapeut akcea-ttr-lrx hattr amyloidosi patient enrol
multicent open-label studi receiv either subcutan inject akcea-ttr-lrx everi week
inotersen per week week patient inotersen refer arm crossov akcea-ttr-lrx
harvard mit announc plan creat center advanc biolog innov manufactur cell
gene therapi boston area privat nonprofit center fund mm partner
includ local univers hospit corpor state offici expect open separ
novarti announc inaugur cell gene therapi gt product facil stein switzerland two
announc highlight us trend toward increas recognit import manufactur cell
gene therapi program variou industri stakehold
look forward decemb decemb decemb fer pharmaceut privat present
societi urolog oncolog suo annual meet washington dc decemb american
societi hematolog meet held baltimor program includ allogen therapeut unrat
unrat buy unrat uniqur buy chardan top pick
decemb unrat present american epilepsi societi
meet baltimor
weekli price move vivo genet medicin aav srna mrna vivo gene edit
srna mrna mm vivo gene edit mm contributor buy mm
note mdco mm month novemb track genet medicin
portfolio due mdco lack rnai platform
upcom chardan genet medicin event contact chardan rsvp
gene express aavhsc-bas vector improv gt
studi publish novemb plo one research unrat character
biodistribut cynomolgu macaqu clade aav vector deriv normal human hematopoiet
stem cell anim dose singl iv administr either vg/kg vg/kg
vg/kg aavhsc previous shown cross blood-brain barrier
pleas refer import disclosur inform regul analyst certif found page report
bbb intraven iv inject mous studi macaqu vector show widespread distribut
central nervou system multipl peripher tissu measur presenc fluoresc report
transgen vector genom dna transduct highest later genicul nucleu lgn pon
red nuclei glial cell primarili target cell though neuron also transduc peripher nervou
system vector detect neuron glial cell sensori ganglia spinal cord key take-away
studi us potenti aavhsc-bas vector cross blood brain barrier transduc select
tissu non-human primat model work perform non-human primat signific differ
neurotrop report mice non-human primat would therefor expect cynomolgu
macaqu repres reliabl predictor tropism human compar mous model
note disord emerg diseas area gt parkinson diseas exampl meiragtx buy
unrat develop therapeut respect research
publish march homolog report neutral antibodi
repres human popul suggest patient may amen treatment use
vector notabl zolgensma market unrat novarti use capsid clade aav known
cross blood brain barrier follow single-dos intraven administr us data collect support
use aavhsc target diseas nervou system though mechan clade aav cross
bbb yet fulli understood homolog current advanc gene therapi metachromat
leukodystrophi mld lysosom storag disord character neurolog deterior ind-en
studi test iv administr phase i/ii studi phenix phenylketonuria
neutral sno data hint efficaci subgroup qs remain novemb livshit
clinic collabor report novemb full result phase trial evalu
fc recurr high-grad glioma rhgg recal trial miss primari secondari endpoint
final readout compani subsequ announc restructur
result analysi pre-specifi subgroup show longer mo patient hgg recurr
mo month regimen vs month standard care chemotherapi bevacizumab hazard
ratio furthermor trend toward longer os observ patient mutat
well patient present anaplast astrocytoma aa oppos glioblastoma
hint efficaci recurr subgroup interest mechan would occur
clear us addit stronger perform recurr patient rais question regard
prospect plan phase ii/iii studi fc newly-diagnos glioblastoma might
expect earlier-stag patient less like benefit
mdco buy predict confirmednovarti buy mdco bn novemb amusa
medicin compani chardan top pick time deal announc acquisit novarti
unrat announc bn repres premium mdco unaffect
share price premium unaffect one-week averag price
mdco avexi nightstar therapeut anoth actual genet medicin predict lead
analyst analyst current top idea uniqur buy chardan top pick
overal anoth seri good year perform chardan top pick chardan
top pick novemb research averag return sinc inclus portfolio
mdco downgrad neutral return chardan top pick novemb amusa
medicin compani enter definit agreement acquir novarti unrat
confirm long-held top-of-consensu bullish view play
mdco trade announc acquisit price limit scope out-performance
therefor downgrad mdco buy neutral remov compani chardan top pick
portfolio thu lock absolut return mdco close prior
made mdco chardan top pick januari research
ocgn buy pt believ unappreci posit enterpris valu novemb naka
initi coverag ocugen buy rate base potenti broad pipelin innov
therapi address rare underserv ophthalmolog diseas market valu cash
forecast mm risk-adjust sale clinic product compani pipelin
driver buy rate
page
 ocugen develop gene therapi treat nuclear hormon receptor gene may benefit
perform toxicolog manufactur prepar specif receptor gene streamlin preclin
studi manufactur us could drive signific advantag effici speed market
 ocugen test agonist phase studi patient ocular
graft-vs-host diseas indic see near-term opportun top-lin result due
 compani manufactur agreement gt cansino biolog unrat
us enabl ocugen better execut ind-en task plan phase i/iia trial next
year deliv function copi nuclear hormon receptor gene retina treat
buy pt rais pt model updat pipelin program novemb naka
arrowhead seen increas share price week sinc compani host
 day octob rais price target basi recent catalyst potenti futur
revenu stream compani preclin program key driver price increas
 rais probabl success compani rnai therapeut patient
chronic hepat viru infect basi posit phase i/ii safeti data note compani also
receiv mm mileston payment follow dose patient trial janssen advanc
phase iib trial chronic hepat viru infect
 arrowhead report aha scientif session addit new posit singl ascend dose data
phase studi rnai therapeut cardiometabol disord base
safeti data evid knockdown preliminari report activ increas probabl success
program
 investor interest rnai therapeut us posit arrowhead compani expect
product clinic includ aro-aat pivot studi
highlight recent event drive investor interest rnai space includ announc new
collabor novo nordisk unrat dicerna buy definit agreement novarti
acquir medicin compani per share
genet medicin news novemb novemb
ise neutral announc appointmentof dr guangp gao chief strategist gt novemb
fer pharma privat announc format jv develop gt bladder cancer novemb
fer pharmaceut blackston lifesci announc joint invest mm establish
fergen privat potenti commerci nadofaragen firadenovec us patient
nadofaragen firadenovec adenovirus-bas therapi current phase trial infinit receiv
unrat initi unrat piii trial antisens tx akcea-ttr-lrx hattr novemb
harvard mit collabor other advanc cell gt innov manufactur novemb
harvard univers mit lead public-priv partnership compris local area hospit corpor
academ institut state offici partnership plan build current unnam facil de-risk
develop innov approach manufactur product cell gene therapi partner pledg
mm expect facil open
recal august unrat announc plan invest mm compani north carolina
manufactur facil recent advanc invest gene therapi manufactur us underscor
import manufactur success gene therapi program howev state februari
research often manufactur capac overlook consensu valuat aav-bas gt compani
cber publish cytidin deaminase-medi base edit human ipsc novemb
buy report fiscal year result provid corpor updat novemb
fbio unrat announc price public offer seri prefer stock novemb
unrat announc appoint jame meyer board director novemb
lonn-ch unrat collabor dinaqor advanc gt cardiomyopathi novemb
page
lonza unrat dinaqor privat collabor develop aav-bas gene therapi program patient
monogen cardiomyopathi term deal lonza provid dinaqor support preclin
clinic commerci product dinaqor lead program
current ind-en studi treatment cardiac myosin-bind protein-c
cardiomyopathi condit associ heart failur dinaqor also develop loco-region deliveri
system deliv directli cardiac muscl cardiac disord us emerg diseas area may
benefit technolog develop treat genet disord musculoskelet system compani pursu
genet medicin heart failur includ biotech privat intrexon unrat miragen unrat
buy buy
mh hannov publish crispr-bas insert locu novemb
upenn publish express follow administr hors novemb
bntc unrat announc intent re-domicil australia unit state novemb
uflorida publish method expand tumor-react t-cell brain tumor novemb
nv unrat announc open gt manufactur facil stein switzerland novemb
dnarx privat publish non-vir dna- liposom base gene deliveri platform novemb
cyad unrat announc appoint ceo filippo petti board director novemb
imba publish sgrna express cassett use crispr gene edit technolog novemb
harvard publish multiplex phenotyp analysi capsid gene novemb
compani mention report
page
page
select catalyst genet medicin coverag
figur regenxbio rocket solid uniqur expect import data read-out
report initi phase data process fanconi anemia
provid follow-up data piib dose-confirm studi hemb
initi phase data patient leukocyt adhes deficiency-i lad-i
initi phase i/ii clinic trial huntington diseas
initi phase i/ii trial dmd nationwid children hospit
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
submit ind methylmalon acidemia mma
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
initi dose phase trial hemophilia
report biomark data phase i/ii ignit dmd trial
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
file ind huntington diseas program
present preclin data new gt program fabri pomp defici
file ind cta pomp diseas
provid updat phase i/ii studi hemophilia
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
page
select catalyst outsid genet medicin coverag
report initi phase i/ii data transfusion-depend thalassemia
bay report initi phase i/ii data hemophilia
report long-term follow-up data wiskott-aldrich syndrom
report data phase trial r/r aml md
report initi data phase i/iia trial r/r nhl
lentiglobin report addit data trial tdt sickl cell diseas
initi pivot phase trial rdeb
suvodirsen interim data open-label extens studi dmd
initi phase ib trial beta-thalassemia
initi clinic trial charcot-marie-tooth type
micro-dystrophin initi pivot trial duchenn muscular dystrophi
initi phase ii studi overact bladder
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
file ind inherit amyotroph later sclerosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
lentiglobin initi phase studi sickl cell diseas
zynteglo initi roll bla submiss fda tdt
report initi data phase i/ii trial phenylketonuria pku
file ind gangliosidosi
dose patient optim lenti vector trial fabri diseas
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma buy lysogen oncosec medic oxford biomedica neutral vbl buy
figur select price movement week end vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm abeona genet therapytickerratingccm ptupsideclosechang changemc mm arrowhead gene editingtickerratingccm ptupsideclosechang changemc mm precis pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap pharmaceut
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid technolog pharmaceut
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name bntx model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani pharmaceut
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis feldan recombinet trucod gene repair verv technolog pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
ultragenyx genetx
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
